Ask AI
ProCE Banner Activity

DeLLphi-303: Updated Phase Ib Results of 1L Maintenance Therapy With Tarlatamab + PD-L1 Inhibitor in Extensive-Stage SCLC

Conference Coverage
Slideset

An update of the phase Ib DeLLphi-303 trial reported that first-line maintenance therapy with tarlatamab plus a PD-L1 inhibitor (either atezolizumab or durvalumab) demonstrated long-term tolerability and no new safety signals in patients with extensive-stage small-cell lung cancer.

Released: November 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.